We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Antibe Therapeutics Inc | TSX:ATE | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.295 | 0.09 | 0.09 | 0 | 01:00:00 |
TORONTO, Aug. 21, 2023 /CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group.
The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View From The C-Suite visit https://www.tmxmoney.com/en/csuite.html.
About Antibe Therapeutics (TSX: ATE)
Antibe Therapeutics is a clinical-stage biotech company developing next-generation, safer medicines for pain and inflammation. The company's proprietary drug platform is designed to overcome the gastrointestinal ulcers and bleeding associated with NSAIDs, a class of drugs used by most North Americans and by billions of people globally. https://antibethera.com/
CNW sponsored announcement. To learn more visit www.newswire.ca.
View original content to download multimedia:https://www.prnewswire.com/news-releases/toronto-stock-exchange-antibe-therapeutics--inc-view-from-the-c-suite-301905939.html
SOURCE Toronto Stock Exchange
Copyright 2023 Canada NewsWire
1 Year Antibe Therapeutics Chart |
1 Month Antibe Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions